Business ❯ Finance ❯ Stock Market ❯ Pharmaceutical Stocks

Novo Nordisk

FDA-Cleared Wegovy Pill Becomes First Oral GLP-1 for Weight Loss

Novo is undercutting rivals on cash pricing to seize early share among self-pay users.

Stories older than 24h

FDA Approves Novo Nordisk’s Wegovy Pill, First Oral GLP-1

Novo Nordisk’s Oral Semaglutide Fails to Slow Alzheimer’s in Dual Phase 3 Trials

Novo Nordisk Cuts 2025 Outlook and Names New CEO as Shares Plunge